担がん患者における化学療法に対するCOVID-19の影響について

  • 中川 幸紀
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部
  • 岡田 雅弥
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部
  • 三宅 美有紀
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部
  • 大本 奈緒子
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部
  • 細 直子
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部
  • 中谷 亮介
    日本赤十字社 徳島赤十字病院 薬剤部
  • 阪口 臨
    独立行政法人労働者健康安全機構 和歌山労災病院 血液内科
  • 下川 福子
    独立行政法人労働者健康安全機構 和歌山労災病院 薬剤部

書誌事項

タイトル別名
  • Influence of COVID-19 on Chemotherapy in Cancer Patient

この論文をさがす

説明

<p>When a patient with cancer becomes infected with COVID-19, disease progression occurs due to the disease becoming more severe or treatment for the underlying disease being interrupted. We investigated the outcome of COVID-19 in cancer patients and the influence on the effect of chemotherapy. The subjects were 45 patients with COVID-19 among 258 cancer patients who were hospitalized and underwent chemotherapy from January 2022 to February 2023.</p> <p>The incidence rate of COVID-19 for each cancer type was 26.8% for blood cancer, 25.0% for lung cancer, and 11.0% for other cancers, with blood cancer and lung cancer significantly higher than other cancers. In addition, the median number of days required for Ct value ≥ 35 was 43.5 days in blood cancer patients, which was significantly longer than in lung cancer patients and other cancer patients. Of the 45 patients infected with COVID-19, 28 patients were infected during chemotherapy, and the median time from chemotherapy to infection with COVID-19 was 14 days. Twenty patients postponed chemotherapy, and the median number of postponed days was 20 days. Death within 30 days of infection with COVID-19 was observed in 2 cases of hematological cancer, 1 of which was due to exacerbation of the primary disease due to the postponement of chemotherapy. This study suggests that COVID-19 may affect the disease prognosis of cancer patients.</p>

収録刊行物

  • 医療薬学

    医療薬学 50 (4), 188-197, 2024-04-10

    一般社団法人日本医療薬学会

参考文献 (19)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ